Clinical trial
A Phase 2, Randomised, Double-blind, Positive-controlled, Multicentre Study of Tiprogrel in the Treatment of Patients with Acute Minor Ischaemic Stroke or High-risk Transient Ischaemic Attack.
NCT06601127 is registered in ClinicalTrials.gov with Tianjin Institute of Pharmaceutical Research Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomised, Double-blind, Positive-controlled, Multicentre Study of Tiprogrel in the Treatment of Patients with Acute Minor Ischaemic Stroke or High-risk Transient Ischaemic Attack.
- Lead sponsor
- Tianjin Institute of Pharmaceutical Research Co., Ltd
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- February 21, 2025
- Completion date
- June 1, 2026
- Enrollment
- 600 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.